Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.